Compare SXC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | DRTS |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | Israel |
| Employees | 848 | 125 |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.8M | 546.5M |
| IPO Year | 2011 | N/A |
| Metric | SXC | DRTS |
|---|---|---|
| Price | $6.59 | $6.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.00 | $8.67 |
| AVG Volume (30 Days) | ★ 1.9M | 225.1K |
| Earning Date | 04-29-2026 | 03-09-2026 |
| Dividend Yield | ★ 7.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,600,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $965.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $2.30 |
| 52 Week High | $9.82 | $8.60 |
| Indicator | SXC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 41.38 |
| Support Level | $6.57 | $6.37 |
| Resistance Level | $6.97 | $7.75 |
| Average True Range (ATR) | 0.29 | 0.42 |
| MACD | 0.13 | -0.06 |
| Stochastic Oscillator | 80.49 | 21.44 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.